Formulation and ex vivo Evaluation of Solid Lipid Nanoparticles (SLNS) Based Hydrogel for Intranasal Drug Delivery

Authors: Pramod Jagtap, Kisan Jadhav, Neha Dand

Abstract:

Risperidone (RISP) is an antipsychotic agent and has low water solubility and nontargeted delivery results in numerous side effects. Hence, an attempt was made to develop SLNs hydrogel for intranasal delivery of RISP to achieve maximum bioavailability and reduction of side effects. RISP loaded SLNs composed of 1.65% (w/v) lipid mass were produced by high shear homogenization (HSH) coupled ultrasound (US) method using glycerylmonostearate (GMS) or Imwitor 900K (solid lipid). The particles were loaded with 0.2% (w/v) of the RISP & surface-tailored with a 2.02% (w/v) non-ionic surfactant Tween® 80. Optimization was done using 32 factorial design using Design Expert® software. The prepared SLNs dispersion incorporated into Polycarbophil AA1 hydrogel (0.5% w/v). The final gel formulation was evaluated for entrapment efficiency, particle size, rheological properties, X ray diffraction, in vitro diffusion, ex vivo permeation using sheep nasal mucosa and histopathological studies for nasocilliary toxicity. The entrapment efficiency of optimized SLNs was found to be 76 ± 2%, polydispersity index <0.3., particle size 278 ± 5 nm. This optimized batch was incorporated into hydrogel. The pH was found to be 6.4 ± 0.14. The rheological behaviour of hydrogel formulation revealed no thixotropic behaviour. In histopathology study, there was no nasocilliary toxicity observed in nasal mucosa after ex vivo permeation. X-ray diffraction data shows drug was in amorphous form. Ex vivo permeation study shows controlled release profile of drug.

Keywords: Ex vivo, particle size, risperidone, solid lipid nanoparticles.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1099106

References:

[1] W. M. Pardridge, “Brain drug targeting, the future of brain drug development”, Cambridge University Press, Cambridge, 2001.
[2] A. Tsuji, “Specific mechanisms for transporting drugs into brain”. In: Begley DJ, Bradbury MW, Kreuter J, editors. The Blood-Brain Barrier and Drug Delivery to the CNS. Marcel Dekker. New York: 2000. pp. 121-144.
[3] S. Talegaonkar, P. R. Mishra, “Intranasal delivery: An approach to bypass blood brain barrier”, Indian J Pharmacol, vol 36(3), pp. 140-147, 2004.
[4] L. Astic, D. Saucier, P.Coulon, “The CVS strain of rabies virus as transneuronal tracer in the olfactory system of mice”, Brain Res., vol 619(1-2), pp. 146-156, 1993.
[5] V. Soni, M. K. Chaurasia, Y. Gupta, et al, “Novel approaches for drug delivery to the brain”, Ind J Pharm Sci, vol 66(6), pp. 711-720, 2004.
[6] Gabathuler, “Approaches to transport therapeutic drugs across the bloodbrain barrier to treat brain diseases”, Neurobiol Dis, vol 37, pp. 48-57, 2010.
[7] L. Illum, “Bioadhesive formulations for nasal peptide delivery: fundamentals, novel approaches and development”, In: Mathiowitz E, Chickering DE, Lehr CM editor. Marcel Dekker. New York: 1999. pp. 507-539.
[8] J. Aurora, “Development of nasal delivery systems: a review”, Drug DelivTechnol, vol 2(7), pp.1-8, 2002.
[9] G. L. Amidon, H. Lennernas, V. P. Shah, et al, “A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability”, Pharm Res, vol 12(3), pp. 413-420, 1995.
[10] H. Van de Waterbeemd, “The fundamental variables of the biopharmaceutics classification system (BCS): a commentary”, Eur J Pharm Sci, vol 7(1), pp.1-3, 1998.
[11] J. B. Dressman, C. Reppas, “In vitro-in vivo correlations for lipophilic, poorly water soluble drugs”, Eur J Pharm Sci, vol 11(2), pp. 73-80, 2000.
[12] G. Barratt, “Colloidal drug carriers: achievements and perspectives”, Cell Mol Life Sci, vol 60(1), pp. 21-37, 2003.
[13] R. H. Muller, S. Heinemann, “Fat emulsions for parenteral nutrition. I. evaluation of microscopic and laser light scattering methods for the determination of the physical stability”, Clin Nutr, vol 11, pp. 223-236, 1992.
[14] C. Vitorino, F. A. Carvalho, A. J. Almeida et al, “The size of solid lipid nanoparticles: An interpretation from experimental design”, Colloids Surf B Biointerf, vol 84, pp. 117-130, 2011.
[15] J. S. Lucks, R. H. Müller, “Medication vehicles made of solid lipid particles (solid lipid nanospheres (SLN)”, EP0000605497, 1996.
[16] P. Ekambaram, A. Abdul HasanSathali, K. Priyanka, “Solid lipid nanoparticles: A review”, Sci Revs Chem Commun, vol 2(1), pp. 80- 102, 2012.
[17] S. Mukherjee, S. Ray, R. Thakur, “Solid lipid nanoparticles: A modern formulation approach in drug delivery system”, Indian J Pharm Sci, vol 71(4), pp. 349-358, 2009.
[18] M. Uner, G. Yener, “Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives”, Int J Nanomedicine, vol 2(3), pp. 289-300, 2007.
[19] C. R. Behl, H. K. Pimplaskar, A. P. Sileno et al, “Effects of physicochemical properties and other factors on systemic nasal delivery”, Adv Drug Del Rev, vol 29, pp. 89-116, 1998.
[20] L. Li, I. Nandi, K. H. Kim, “Development of an ethyl laurate based microemulsion for rapid-onset intranasal delivery of diazepam”, Int J Pharm, vol, 237, pp. 77-85, 2002.
[21] L. G. Candace, G. M. Pollock, “Nasal drug administration: potential for targeted central nervous system delivery”, J Pharm Sci, vol 94, pp. 187- 195, 2005.
[22] Y. Lu, X. Tang, Y. Cui et al, “In vivo evaluation of risperidone SAIB in situ system as a sustained release delivery system in rats”, Eur J Pharm Biopharm, vol 68, pp. 422-429, 2008.
[23] A. C. Silva, M. H. Amaral, E. González-Mira et al, “Solid lipid nanoparticles (SLN) - based hydrogels as potential carriers for oral transmucosal delivery of risperidone: Preparation and characterization studies” Colloids Surf B Biointerf, vol 93, pp. 241-248, 2012.
[24] U. Bertram, R. Bodmeier, “In situ gelling, bioadhesive nasal inserts for extended drug delivery: In vitro characterization of a new nasal dosage form”, Eur J Pharm Sci, vol 27, pp. 62-71, 2006.
[25] S. Singh, M. Kumar, T. Singh et al, “Hydrogels used as a potential drug delivery system: A review”, International Journal of Pharmaceutical & Biological Archives, vol 2(4), pp. 1068-1076, 2011.
[26] K. Vermani, S. Garg, L. J. Zaneveld, “Assemblies for in vitro measurement of bioadhesive strength and retention characteristics in simulated vaginal environment”, Drug DevInd Pharm, vol 28(9), pp. 1133-1146, 2002.
[27] M. Kumar, K. Pathak, “Formulation and characterization of nanoemulsion-based drug delivery system of risperidone”, Drug DevInd Pharm, vol 35, pp. 387-395, 2009.
[28] P. V. Pople, K. K. Singh, “Development and evaluation of colloidal modified nanolipid carrier: application to topical delivery of tacrolimus” Eur J Pharm Biopharm, vol 79(1), pp. 82-94, 2011.
[29] A. C. Silva, E. González-Mira, M. L. García et al, “Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): High pressure homogenization versus ultrasound”, Colloids Surf B Biointerf, vol 86, pp. 158-165, 2011.
[30] E. Gonzalez-Mira, M. A. Egea, M. L. Garcia et al, “Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC”, Colloids Surf B Biointerf, vol 81, pp. 412-421, 2010.
[31] J. Y. Fang, C. L. Fang, C. H. Liu et al, “Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC)”, Eur J Pharm Biopharm, vol 70, pp. 633-640, 2008.
[32] O. V. Olesen, K. Linnet, “Simplified high-performance liquid chromatographic method for determination of risperidone and 9- hydroxyrisperidone in serum from patients co-medicated with other psychotropic drugs”, J Chromatography, vol 698, pp. 209-216, 1997.
[33] A. A. Date, N. Vador, A. Jagtap et al, “Lipid nanocarriers (GeluPearl) containing amphiphilic lipid Gelucire 50/13 as a novel stabilizer: fabrication, characterization and evaluation for oral drug delivery”, Nanotechnology, vol; 22, pp. 1-12, 2011.
[34] Z. Rahman, A. S. Zidan, M. A. Khan, “Non-destructive methods of characterization of risperidone solid lipid nanoparticles”, Eur J Pharm Biopharm, vol 76, pp. 127-137, 2010.
[35] M. Kumar, A. Misra, K. Pathak, “Formulation and characterization of nanoemulsion of olanzapine for intranasal delivery”, PDA J Pharm Sci and Tech, vol 63, pp. 501-511, 2009.
[36] L. I. Giannola, V. D. Caro, G. Giandalia et al, “Release of naltrexone on buccal mucosa: permeation studies, histological aspects and matrix system design” Eur J Pharm Biopharm, vol 67, pp. 425-433, 2007.
[37] G. Samson, A. G. Calera, S. D. Girod et al, “Ex vivo study of bevacizumab transport through porcine nasal mucosa”, Eur J Pharm Biopharm, vol 80, pp. 465-469, 2012.
[38] V. Jenning, S. Gohla, “Comparison of wax and glyceride solid lipid nanoparticles (SLN®)”, Int J Pharm, vol 196(2), pp. 219-22, 2000.
[39] B. D. Kim, H. K. Choi, “Preparation and characterization of solid lipid nanoparticles (SLN) made of cacao butter and curdlan”, Eur J Pharm Sci, vol 24(2-3), pp. 199-205, 2005.
[40] E. B. Souto, S. A. Wissing, C. M. Barbosa et al, “Evaluation of the physical stability of SLN and NLC beforeand after incorporation into hydrogel formulations”, Eur J Pharm Biopharm, vol 58, pp. 83-90, 2004.